Ironwood Pharmaceuticals, Inc.
Ironwood Pharmaceuticals, Inc. (IRWD) Revenue
Annual & quarterly revenue history · segment & region breakdown
IRWD · revenue · updated Jun 8, 2026
Core revenue metrics
Trailing 12 monthsIronwood Pharmaceuticals, Inc. trailing twelve-month (TTM) revenue is $0.36B, a decrease of 15.72% year-over-year from $0.30B in FY2025.
Revenue trend
2025 – 2006 · AnnualRevenue history
| Fiscal year end | Revenue | Change | Growth |
|---|---|---|---|
| 2025-12-31 | $0.30B | -$0.06B | -15.72% |
| 2024-12-31 | $0.35B | -$0.09B | -20.63% |
| 2023-12-31 | $0.44B | +$0.03B | +7.83% |
| 2022-12-31 | $0.41B | -$0.00B | -0.76% |
| 2021-12-31 | $0.41B | +$0.02B | +6.22% |
| 2020-12-31 | $0.39B | -$0.04B | -9.08% |
| 2019-12-31 | $0.43B | +$0.08B | +23.59% |
| 2018-12-31 | $0.35B | +$0.05B | +16.21% |
| 2017-12-31 | $0.30B | +$0.02B | +8.88% |
| 2016-12-31 | $0.27B | +$0.12B | +83.18% |
Revenue breakdown
Segment & GeographyAbout Revenue & Reporting
Revenue (also called sales, net sales, or turnover) is the total income Ironwood Pharmaceuticals, Inc. receives from its business operations before deducting any costs or expenses. It is the top line of the income statement. Unlike net income or earnings, revenue does not account for operating costs, taxes, interest, or depreciation.
Ironwood Pharmaceuticals, Inc. reports revenue on a fiscal year ending Dec 31 basis under US GAAP, denominated in USD.
Data sourced from Ironwood Pharmaceuticals, Inc.'s 10-K and 10-Q SEC filings via Financial Modeling Prep.
Frequently asked questions
IRWD revenue · 4 questionsIRWD's trailing twelve-month (TTM) revenue is $0.36B. That is a decrease of 15.72% year-over-year from $0.30B in FY2025.
▸ Source: FMP · Ironwood Pharmaceuticals, Inc. SEC filings · GAAP · Ironwood Pharmaceuticals, Inc. SEC 10-K & 10-Q filings · US GAAP · Updated: Jun 8, 2026